仟源醫藥(300254.SZ)：2020年度由盈轉虧 預虧2.2億元-2.86億元
格隆匯 1 月 30日丨仟源醫藥(300254.SZ)披露2020年度業績預吿，預計2020年歸屬於上市公司股東的淨虧損2.2億元～2.86億元，上年同期盈利529.68萬元；扣除非經常性損益後的淨虧損2.45億元～3.19億元，上年同期虧損5940.01萬元。業績變動原因如下：
1、報吿期內公司營業收入同比有所下降，主要是由於公司重點產品美洛西林鈉舒巴坦鈉、阿莫西林鈉舒巴坦鈉等退出了2019版《國家醫保目錄》，上述產品佔公司營業收入比重較大，報吿期內上述產品營業收入同比降幅較大。此外，報吿期內公司抗感染藥物及呼吸系統藥物受新冠肺炎疫情影響，也出現了較大幅度的銷售下滑。
2、報吿期內，由於受新冠肺炎疫情、我國出生人口持續下降、國家藥品集中採購等原因導致藥品銷售價格降價等因素的影響，子公司杭州保靈集團有限公司、浙江仟源海力生製藥有限公司、杭州仟源恩氏基因技術有限公司等存在商譽減值的跡象，公司根據評估機構對主要子公司商譽減值測試的初步結果計提了商譽減值準備約5200萬元。
3、報吿期內西藏仟源收到了1925.02萬元的產業發展扶持基金，而2019年西藏仟源則收到了4325.02萬元的產業發展扶持基金，導致公司營業外收入同比下降較大。
4、2019年11月，公司與江蘇疌泉醴澤健康產業創業投資基金(有限合夥)(“醴澤基金”)及自然人張宇簽署《關於投資江蘇嘉逸醫藥有限公司之合作協議》，共同設立南通恆嘉藥業有限公司受讓江蘇嘉逸醫藥有限公司的部分股權。協議約定公司對醴澤基金、張宇的出資款負有回購義務。因此，公司將醴澤基金、張宇對南通恆嘉藥業有限公司的出資作為金融負債，並按照約定的年化收益率計提相關金融負債產生的財務費用，導致報吿期內利息支出增加約2430萬元。
5、公司按權益法核算的聯營公司寧波磐霖仟源股權投資合夥企業(有限合夥)(“合夥企業”)對外投資了若干公司，該合夥企業對上述投資無控制、無共同控制、無重大影響，按成本法核算。報吿期內，公司根據評估機構的初步評估結果將合夥企業賬面的長期股權投資調整為以公允價值計量的其他非流動金融資產，並將報吿期內上述其他非流動金融資產的公允價值變動計入報吿期內的公允價值變動損益。報吿期內上述投資收益較2019年度減少約1600萬元。
6、報吿期內，預計非經常性損益對淨利潤的影響約2620萬元，主要為收到各類政府補貼的影響約2790萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
